Physician- and Patient-based Barriers to NGS Testing
Recruiting · NCT07209176 · Interventional (participants receive a specific treatment) · Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View the official record on ClinicalTrials.gov →Interventions studied
Provider-level and patient education at end of studyProvider-level and patient-level
What this trial is about
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Who can take part
Age range
18 Years and older
Sex
Male
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not applicable (e.g. observational or device study)
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- men diagnosed with metastatic prostate cancer
- seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Exclusion criteria
- \- Patients who have already had NGS testing performed.
Where it is running
1 location listed across 1 US state.
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore, Maryland, United States